An anti-COVID-19 therapeutic drug developed by DRDO called drug2-deoxy-D-glucose (2-DG) has been given emergency approval by the Drug Controller General of India (DCGI) for Coronavirus patients in the country. The anti-Covid-19 drug was developed by DRDO last year and has undergone three phases of clinical trials between April 2020 and March 2021. The drug was … Continue reading DCGI gives approval to use anti-Covid drug 2-DG as adjunct therapy for Covid-19 patients